I wonder how IMCR study protocol is going to handle elevated LFTs which have to be expected as T cells are Re-directed against hepatocytes harboring HBV reservoir? May be tricky they want to see some elevation (on target effect) but have to have some way to differentiate from liver tox especially for a virus that already can compromise the liver. Has nothing to do w asmb sorry for the tangent.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.